Seizures Clinical Trial
— KeppraOfficial title:
Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures
Verified date | March 2020 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.
Status | Completed |
Enrollment | 18 |
Est. completion date | October 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 14 Days |
Eligibility |
Inclusion Criteria: - Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with seizures. - Term infants (gestational age greater than or equal to 37 weeks. - > 2500 grams (max blood for study 6mL =3%). - Postnatal age 14 days or less. - Serum creatinine less than 1.2 at time of enrollment. - Received loading dose of phenobarbital 20mg/kg. - Are still experiencing either clinical or electroencephalographic seizures despite this therapy. - For whom parental consent to participate in the study is obtained. Exclusion Criteria: - Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in seizure cessation. - Severe hypoxic ischemic injury likely to result in imminent death - The only significant exclusions that will be made in recruitment and enrollment will be the exclusion of infants who are judged by the attending neonatologist to be so critically ill that death is imminent and benefit from neonatal intensive care is very unlikely. - No rule-based criteria, (using lab or clinical parameters) adequately capture the complete nature of this clinical assessment. - In general any child receiving active treatment with head cooling will not be excluded. - Mechanical ventilation and/or the use of inotropic agents to support blood pressure will not be exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU) | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Richard H. Haas | Thrasher Research Fund |
United States,
Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012 Jul;72(1):43-9 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Drug Clearance | Day 1 and Day 7 | ||
Primary | Drug Half Life | Day 1 and Day 7 | ||
Secondary | Levetiracetam Treated Number of Participants With Serious Adverse Events | 7 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02850913 -
Doxycycline for the Treatment of Nodding Syndrome
|
Phase 2 | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Not yet recruiting |
NCT06045676 -
Electrocardiographic Changes Among Epileptic and Non Epileptic Seizures in Children at Sohag University Hospital
|
||
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02897856 -
Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures
|
Phase 4 | |
Completed |
NCT01239212 -
Dosing of Levetiracetam (Keppra) in Neonates
|
Phase 1/Phase 2 | |
Completed |
NCT01236001 -
Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older
|
N/A | |
Completed |
NCT01703468 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
|
Phase 1 | |
Completed |
NCT01702623 -
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions
|
Phase 1 | |
Recruiting |
NCT02216500 -
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
|
N/A | |
Completed |
NCT00236717 -
A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Completed |
NCT05103735 -
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
|
||
Terminated |
NCT03790436 -
Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet
|
N/A | |
Completed |
NCT06451289 -
Study on Optic Nerve Sheath Diameter Measurements in Prolonged Pediatric Seizures
|
||
Recruiting |
NCT02552511 -
Epidemiology Study on Neonatal Seizure
|
||
Recruiting |
NCT05339126 -
RNS System LGS Feasibility Study
|
Phase 2 | |
Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
Recruiting |
NCT04770337 -
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
|
N/A |